Jamile Frayfer

Meaux, FR 
Meaux, FR 

Overview

Jamile Frayfer practices practicing medicine in Meaux, France.

Their clinical expertise encompasses Acute Lymphoblastic Leukemia (ALL), Leukemia, Multiple Myeloma, Acute Myeloid Leukemia (AML), and Bone Marrow Transplant.

They are actively involved in clinical research, co-authoring 12 peer reviewed articles and participating in 2 clinical trials.

Locations

Meaux, France
Other Locations
La Roche, France
Nantes, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Efficacy of Alternating Immunochemotherapy Consisting of R-CHOP + R-HAD vs R-CHOP Alone, Followed by Maintenance Therapy Consisting of Additional Lenalidomide + Rituximab vs Rituximab Alone for Older Patients With Mantle Cell Lymphoma
Efficacy of Alternating Immunochemotherapy Consisting of R-CHOP + R-HAD vs R-CHOP Alone, Followed by Maintenance Therapy Consisting of Additional Lenalidomide + Rituximab vs Rituximab Alone for Older Patients With Mantle Cell Lymphoma
Enrollment Status: Completed
Publish Date: March 05, 2025
Intervention Type: Drug
Study Drugs: R-CHOP, R-CHOP/R-HAD, Rituximab, Lenalidomide
Study Phase: Phase 3
ESCORT-HU Extension: European Sickle Cell Disease Cohort - Hydroxyurea - Extension
ESCORT-HU Extension: European Sickle Cell Disease Cohort - Hydroxyurea - Extension
Enrollment Status: Unknown
Publish Date: August 27, 2024
Intervention Type: Drug
View 1 Less Clinical Trial

12 Total Publications

Real-world patterns of treatment intensity and prognostic model performance in older acute myeloid leukemia: insights from the French ALFA-PPP Cohort.
Real-world patterns of treatment intensity and prognostic model performance in older acute myeloid leukemia: insights from the French ALFA-PPP Cohort.
Journal: Leukemia
Published: April 14, 2026

Frequently Asked Questions about Jamile Frayfer

Is Jamile Frayfer a top-rated expert for Acute Lymphoblastic Leukemia (ALL)?

MediFind is an objective health platform that identifies experts based on real-world data. Jamile Frayfer is classified as an Experienced expert for Acute Lymphoblastic Leukemia (ALL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Jamile Frayfer participate in research or clinical trials?

Yes. Jamile Frayfer has published 12 articles and abstracts on conditions like Acute Lymphoblastic Leukemia (ALL). You can view a list of Jamile Frayfer's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Frayfer's expertise for a condition
ConditionClose
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile